Arboe B, et al. - Using Danish National Lymphoma Registry, researchers studied the impact of intensity of treatment on survival in diffuse large B-cell lymphoma (DLBCL) patients previously treated with rituximab (n=277) and chemotherapy and analyzed the correlation between socioeconomic position and treatment intensity, defined as palliation, non-salvage, and salvage regimens. A total of 1,228 patients were included with either primary refractory or relapsed disease. The 5-year overall survival (OS) in the rituximab era was 31% for patients receiving salvage regimens and 17% for patients receiving non-salvage regimens. A better OS was observed in patients treated with salvage regimens vs non-salvage regimens. However, this contradicts the adjusted analysis. Furthermore, the results indicate that patients who are not eligible for autologous stem cell transplantation (ASCT) are likely to receive remission.